Nasdaq grants Avalo Therapeutics 180-day extension to regain equity compliance

Avalo Therapeutics, Inc.

Reported stockholders' equity of negative $112.5M as of March 31, 2024, falling short of Nasdaq's $2.5M minimum.
Received Nasdaq Staff deficiency notice on May 20, 2024 for non-compliance with Listing Rule 5550(b)(1).
On July 29, 2024, Nasdaq granted a 180-day extension to November 18, 2024 to regain compliance.
Company submitted a compliance plan; no assurance it will regain compliance by the deadline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.